Half year results discussion
Filed with ASX · · 5 pages · English
® Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the half-year financial results for the six months ended 31 December 2022. Glaucoma Surgical Devices Segment Nova Eye Medical reported group revenues of $6.54 million, attributable almost entirely to the sale of i
In the deck
Story so far
Earlier from Nova Eye Medical
- Glaucoma Sales Update
- EYE AGM Presentation
- US Government Stimulus Loan Forgiven
- Aquisition of Glaucoma Patents
- FY21 Appendix 4E and Annual Report
Later from Nova Eye Medical
- Investor presentation Half Year Results 31 December 2021
- Nova Eye Medical Launches Next Generation Canaloplasty Device for Glaucoma, iTrack™ Advance
- 2RT Pivotal Study and Regulatory Pathway
- AlphaRet Investor Presentation
- iTrack Advance Commercial Roll-Out Commenced
Follow Nova Eye Medical into a list and get an email when it puts out news.
Follow Nova Eye Medical